Antiretroviral Drug Therapy

Introduction and Goals of Antiretroviral Therapy

Antiretroviral therapy (ART) involves using a combination of HIV medicines to slow down the replication of the virus in the body. While ART does not cure HIV, it transforms a fatal infection into a manageable chronic condition.

Viral Suppression: Reducing the viral load in the blood to undetectable levels.
Immune Recovery: Preserving and rebuilding the CD4 T-cell count.
Prevention: Stopping transmission of the virus to sexual partners and from mother to child.
Symptom Reduction: Preventing opportunistic infections and AIDS-related deaths.

Classes of Antiretroviral Drugs and Mechanisms

Antiretroviral medications are grouped into different classes based on the specific phase of the HIV life cycle they interrupt. Combining classes prevents the virus from easily developing resistance.

Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Act as faulty building blocks so the virus cannot copy its genetic material.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Bind directly to and disable the reverse transcriptase enzyme.
Protease Inhibitors (PIs): Block the protease enzyme, stopping the virus from cutting proteins into functional shapes.
Integrase Strand Transfer Inhibitors (INSTIs): Prevent HIV genetic material from integrating into human DNA.

Standard ART Regimens in Nigerian Clinical Practice

National guidelines in Nigeria align with global standards to provide standardized, effective, and tolerable regimens for adults, adolescents, and children. First-line therapy typically consists of two NRTIs combined with an INSTI or an NNRTI.

Regimen Line	Typical Drug Combination	Clinical Application
Preferred First-Line	Tenofovir + Lamivudine + Dolutegravir	Initial treatment for most adults and adolescents
Alternative First-Line	Tenofovir + Lamivudine + Efavirenz	Used when dolutegravir is contraindicated
Standard Second-Line	Zidovudine + Lamivudine + Protease Inhibitor	Prescribed following first-line treatment failure

Patient Assessment and Therapy Initiation

Before initiating treatment, nurses and clinicians must conduct a thorough clinical baseline evaluation. This ensures safe drug selection and establishes markers for future monitoring.

Baseline assessments include determining the WHO clinical staging, measuring CD4 cell count, checking baseline viral load where available, and screening for opportunistic infections like tuberculosis. Renal function tests are essential when prescribing tenofovir. Counseling the patient on adherence before the first pill is swallowed remains critical for long-term success.

Monitoring Efficacy and Recognizing Toxicity

Ongoing monitoring ensures that the prescribed regimen suppresses the virus and remains safe for the patient.

Viral load testing is the gold standard for measuring treatment efficacy, typically performed six months after initiation and annually thereafter if stable. CD4 counts track immune system recovery. Nurses must remain vigilant for drug toxicities, such as peripheral neuropathy from certain NRTIs, rash from NNRTIs, or metabolic changes associated with protease inhibitors.

Promoting Medication Adherence and Retention in Care

Maintaining near-perfect adherence—typically above 95%—is required to suppress viral replication and prevent drug resistance. Nurses play a frontline role in addressing barriers to adherence.

Stigma, pill burden, forgetfulness, and financial constraints often hinder regular clinic attendance. Peer support groups, counseling, multi-month dispensing of drugs, and reminder alarms help patients stay engaged. When clients miss appointments, tracking systems and community health workers facilitate prompt tracing and re-engagement.

Test yourself on this topic →